Research programme: cannabinoid CB2 receptor agonists - AbbVie
Alternative Names: A-796260Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Abbott Laboratories
- Class Indoles; Morpholines; Small molecules
- Mechanism of Action Cannabinoid receptor CB2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Pain
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Pain in USA (Parenteral)
- 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
- 29 Mar 2012 Pharmacodynamics data from a preclinical trial in pain presented at the 243rd American Chemical Society National Meeting (243rd-ACS-2012)